Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.
Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA.
Houghton PJ, et al.
Pediatr Blood Cancer. 2011 Sep;57(3):443-53. doi: 10.1002/pbc.22921. Epub 2010 Dec 27.
Pediatr Blood Cancer. 2011.
PMID: 21744473
Free PMC article.